PMID- 34485342
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210907
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Residual Pain in the Context of Selecting and Switching Biologic Therapy in 
      Inflammatory Rheumatic Diseases.
PG  - 712645
LID - 10.3389/fmed.2021.712645 [doi]
LID - 712645
AB  - For many years, inflammatory rheumatic diseases (IRDs) represented a source of 
      disappointment in medical care caused by the mediocre efficacy of the available 
      treatments. Some of these diseases, like Rheumatoid Arthritis (RA) or Ankylosing 
      Spondylitis (AS), caused fear in the general population, especially due to 
      associated joint deformities and subsequent disabilities. However, in the last 20 
      years, a new successful class of antirheumatic drugs has become available: 
      biologic Disease-Modifying Antirheumatic Drugs (bDMARDs). Due to this innovative 
      treatment, the days are over when joint and spine deformities defined the 
      condition of a person with RA or AS. Nonetheless, expectations are higher today, 
      and other clinical problems, (not entirely solved by bDMARDs), seem to drive the 
      drug selection during the span of rheumatic diseases. Most of these issues are 
      covered by the term "unmet needs." One of the most intriguing of such needs is 
      the residual pain (RP) in patients that are otherwise in the biological remission 
      of the disease. Present in a significant proportion of the patients that enter 
      remission status, RP is poorly understood and managed. In recent years, new data 
      has become available in this area and new conceptual clarifications have 
      occurred. In this review, we explain the various nature of RP and the necessity 
      of treatment diversification in such situations. All in all, we believe this 
      condition is far more complex than simple pain and includes other clinical 
      aspects, too (like fatigue or mood changes) so the terms Post-Remission Syndrome 
      (PRS), and PRS pain might be more appropriate.
CI  - Copyright (c) 2021 Berghea, Berghea, Zaharia, Trandafir, Nita and Vlad.
FAU - Berghea, Florian
AU  - Berghea F
AD  - Department of Rheumatology, Carol Davila University of Medicine and Pharmacy, 
      Bucharest, Romania.
AD  - Sf. Maria Hospital, Bucharest, Romania.
FAU - Berghea, Camelia Elena
AU  - Berghea CE
AD  - Department of Rheumatology, Carol Davila University of Medicine and Pharmacy, 
      Bucharest, Romania.
AD  - Marie Curie Emergency Children's Hospital, Bucharest, Romania.
FAU - Zaharia, Dumitru
AU  - Zaharia D
AD  - Sf. Maria Hospital, Bucharest, Romania.
FAU - Trandafir, Andreea Iulia
AU  - Trandafir AI
AD  - Sf. Maria Hospital, Bucharest, Romania.
FAU - Nita, Elena Cristina
AU  - Nita EC
AD  - Sf. Maria Hospital, Bucharest, Romania.
FAU - Vlad, Violeta Maria
AU  - Vlad VM
AD  - Sf. Maria Hospital, Bucharest, Romania.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210817
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8415826
OTO - NOTNLM
OT  - ankilosing spondylitis
OT  - biologic therapy
OT  - disease modifying anti-rhuematic drugs
OT  - post remission syndrome
OT  - remission
OT  - residual pain
OT  - rheumatod arthritis
OT  - switch
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/09/07 06:00
MHDA- 2021/09/07 06:01
PMCR- 2021/08/17
CRDT- 2021/09/06 06:07
PHST- 2021/05/20 00:00 [received]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/09/06 06:07 [entrez]
PHST- 2021/09/07 06:00 [pubmed]
PHST- 2021/09/07 06:01 [medline]
PHST- 2021/08/17 00:00 [pmc-release]
AID - 10.3389/fmed.2021.712645 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Aug 17;8:712645. doi: 10.3389/fmed.2021.712645. 
      eCollection 2021.